Calliditas' Kinpeygo, an IgA Nephropathy Targeted Therapy, Receives Conditional Approval from EMA, Paving the Way for Expansion in the European Market
Background on the First Targeted Therapy for IgA Nephropathy Approved in Europe
The European Medicines Agency (EMA) granted conditional marketing authorization for Kinpeygo (budesonide), a treatment for primary Immunoglobulin A Nephropathy (IgAN) developed by Calliditas Therapeutics, on July 15, 2022. This decision recognizes its innovative approach as the first targeted therapy that locally inhibits the production of galactose-deficient IgA1 (Gd-IgA1), a modified protein found in gut-associated lymphoid tissue (GALT), thereby preventing glomerular damage in the kidneys. Previously, with limited targeted treatment options beyond systemic corticosteroids, many patients progressed to end-stage renal disease (ESRD). This approval marks a significant milestone, offering patients a new therapeutic alternative.
Clinical Phase 3 Data Demonstrating Preservation of Kidney Function
The approval of Kinpeygo is based on data from the global Phase 3 NefIgArd study, which demonstrated statistically significant efficacy and an improved safety profile compared to placebo. Patients in the Kinpeygo group showed a delayed rate of decline in estimated Glomerular Filtration Rate (eGFR), indicating a noticeable slowing of the progression of kidney function. Additionally, the Urine Protein-to-Creatinine Ratio (UPCR) was significantly reduced. The innovative delayed-release technology minimizes the adverse events associated with systemic steroid administration, thereby improving long-term treatment compliance. This clinical efficacy is expected to lead to full marketing authorization from the EMA in 2024.
Structure of the Commercialization Licensing Agreement with STADA in Europe
To facilitate rapid commercialization in the European market, Calliditas has entered into an exclusive licensing agreement with STADA Arzneimittel AG, a German pharmaceutical company, to actively expand its presence in Europe. The total deal value is EUR 97.5 million (approximately USD 115 million), with an upfront payment of EUR 20 million received upon signing. Milestone payments based on regulatory and commercial achievements are capped at EUR 77.5 million. With the full marketing authorization obtained in 2024, an additional milestone payment of EUR 10 million was received. The agreement also includes tiered royalties based on STADA's sales, creating a structure that is expected to generate long-term revenue.
Increasing Market Competition and Future Market Outlook
The global market for IgA nephropathy treatments is estimated at USD 1.5 billion in 2025 and is projected to grow at a rapid rate of over 10% annually, making it an attractive market. Travere Therapeutics' Filspari (sparsentan), a dual angiotensin II and endothelin receptor antagonist (DEARA), is emerging as a strong competitor with a non-immunosuppressive mechanism of action. Novartis is also aggressively expanding its pipeline with therapies such as sibeprenlimab and iptacopan, further diversifying the competitive landscape. However, Kinpeygo has secured Orphan Drug Designation in Europe, granting it market exclusivity until 2032, which provides a significant advantage in defending its initial market share.
Calliditas' Kinpeygo's conditional approval in Europe provides the first targeted treatment option in the rare kidney disease market of IgA nephropathy, positioning the company to capture a share of the market projected to reach USD 1.5 billion by 2025. From an investor's perspective, the upfront payment of EUR 20 million and the additional EUR 10 million milestone payment received in 2024 with full approval demonstrate the validity of the USD 1.18 billion valuation in the Asahi Kasei acquisition. For clinical and research teams, the Phase 3 NefIgArd data provides a successful case study of a delayed-release formulation that minimizes immunosuppressive side effects, demonstrating the ability to preserve eGFR. Industry professionals can use this as a benchmark to predict the market share competition with other non-immunosuppressive therapies, such as Travere Therapeutics' Filspari. In the short term, revenue growth will be driven by the distribution network of its European partner, STADA, while in the medium to long term, the market exclusivity in Europe until 2032 will be a key driver of performance.
Source: EMA (ema)